CCL5 and neoplasm: Our study also indicates that two tumor-infiltrating NK cell subsets, CD16+ and CD16- CD103+ , could be the initial suppliers of CCL5 and IFNɣ during chemotherapy and anti-HER2 antibody treatment in human breast tumors.